Seagen SGEN shares are trading higher after the company, along with Genmab A/S GMAB, announced the FDA has granted accelerated approval to TIVDAKTM for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Seagen's stock is trading up 6.2% to a price of $168.92. The stock's current volume for the day is 365.81 thousand, which is approximately 55.63% of its previous 30-day average volume of 657.62 thousand.
The moving average price of the stock over the past 50 days was $154.51 at the time this article was published. In the past fifty-two weeks, the stock price has been as high as $213.94 and as low as $133.2.
If you're looking for timely and concise explanations of why a stock is moving, check out Benzinga Pro. Subscribers get ‘Why Is It Moving' alerts as soon as our research team identifies the cause of the price action in a stock. Click here to learn more.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
